Abstract Objectives: To evaluate the efficacy of prednisolone and/or acyclovir in the treatment of Bell's palsy in relation to severity at the first visit.
Introduction
Bell's palsy is an abrupt onset of unilateral weakness or paralysis of the face with no obvious cause. 1 The annual incidence is about 30 per 100,000 population, with no seasonal or geographical clustering and with a peak incidence between the second and fourth decades of life. 2, 3 The aetiology is still unknown, but reactivation of latent herpes virus, with subsequent inflammation and entrapment of the facial nerve in the narrow labyrinthine segment, is one proposed mechanism for the nerve injury. 4, 5 In most cases, the natural course of Bell's palsy is favourable; however, approximately 30% of patients will suffer some sequelae, and 4% will have severe sequelae with contracture and/or synkinesis. 2 Treatment for Bell's palsy is aimed to prevent sequelae and is based on the presumed pathophysiology of herpes virus infection and inflammation of the facial nerve. 6, 7 In a recent study, it was stated that corticosteroids significantly increased the frequency of complete recovery from Bell's palsy. 8 In a study done by Lockhart et al. 6 with 1987 patients in seven trials, however, a significant benefit from antivirals compared with placebo was not shown.
Previous studies have reported that severe palsy is a negative prognostic factor for recovery from Bell's palsy. [9] [10] [11] [12] Despite the finding that corticosteroids improve the recovery rates in Bell's palsy, the treatment effect in relation to severity of palsy at presentation is largely unknown. In the study done by Lockhart et al. 6 it was concluded that subgroup analysis of existing data and further studies should be performed to assess the impact of baseline severity of palsy on the outcome of treatment. According to Linder et al., 13 studies are needed to verify any benefit of medical treatment in Bell's palsy and herpes zoster oticus paralysis; such studies would have to include analysis of the severity of palsy at baseline.
The aim of the present study is to study the treatment effect of prednisolone and/or acyclovir on outcome of Bell's palsy in relation to severity of palsy at presentation.
Patients and methods

Patients
Patients with acute unilateral peripheral facial palsy were screened by the ear, nose and throat physicians at four public Otorhinolaryngology clinics in Kalubia-Egypt (Benha University Hospital, Benha Insurance Hospital, Benha Educational Hospital and Toukh Insurance Clinic) between January 2010 and May 2012. 625 patients aged 18-70 years with palsy onset within 72 h were considered for inclusion.
Cases presenting after more than 72 h since onset of palsy or patients younger than 18 years or older than 70 years, as well as unwillingness to participate, diabetes mellitus, previous facial palsy, pregnancy or breastfeeding, other neurological diseases, uncontrolled hypertension and psychiatric diseases were excluded from the study. 14 All patients and parents of patients under 21 years old were informed about the study trial and written consents were signed.
Using sealed envelops, patients were randomly allocated in three groups, group 1 included 208 patients and received prednisolone plus placebo, group 2 included 208 patients and received acyclovir plus placebo and group 3 included 209 patients and received prednisolone plus acyclovir.
Grading of facial function was performed by senior ENT specialists using the Sunnybrook facial grading system at start of treatment/baseline at the first visit, and at every follow-up visit. The Sunnybrook grading system is a regionally weighted system that evaluates resting symmetry, degree of voluntary movements and synkinesis. Scores are summed to form a score of 0-100, where 0 is complete paralysis and 100 represents normal functions. 15, 16 Patients in each group were divided into three groups according to severity of palsy at presentation using the Sunnybrook score: severe (Sunnybrook score 0-20); moderate (Sunnybrook score 21-40) and mild (Sunnybrook score >40) 16 .
Procedures
Prednisolone 5 mg (or placebo matched for smell, colour and size) was given as 60 mg daily for 5 days, then tapering by 10 mg per day for 5 days, to give a total treatment time of 10 days. Acyclovir (or placebo matched for smell, colour and size) was given as two 200-mg tablets three times daily for 7 days. Follow-up visits were scheduled at day 14 and at 1, 2, 3, 6 and 12 months. If recovery was complete (Sunnybrook score of 100) in the first months, the next follow-up was at 12 months. Team physicians and patients were blinded for the treatment drugs.
Synkinesis at 12 months was assessed with the Sunnybrook system and classified as present or not present.
The results in this study were presented using Sunnybrook scores because the Sunnybrook facial grading system is more sensitive to sequelae and it is also more reliable. [17] [18] [19] Total recovery at 12 months (Sunnybrook score = 100) and the presence of synkinesis at 12 months were evaluated for correlation to severity of palsy at baseline.
Statistical analysis
The differences in Sunnybrook scores at 12 months between treatment groups were compared by calculating two-sided pvalues based on Wilcoxon's rank sum test. Categorical variables were compared using Fisher's exact test. Univariate Cox proportional hazards models were used to estimate the hazard ratio of recovery. The log rank test was used to test the null hypothesis that there is no difference between treatment groups at any timepoint, taking whole follow-up period into account. All computations were carried out using SPSS software, version 16.
Results
In total, 625 patients (331 men, 294 women) were included in the study. Of these, 208 received prednisolone plus placebo, 208 acyclovir plus placebo and 209 prednisolone plus acyclovir. Of the 625 patients, 603 (315 men, 288 women) attended the 12-month follow-up visit. Age and treatment start were similar in the three groups.
Mean age was 45.82 years (± 14.95) in the patients with severe palsy, 43.87 years (± 14.96) in the moderate and 39.80 years (± 13.51) in the mild palsy group.
Patients with severe palsy at baseline had a mean time to treatment start of 48.42 h (sd ± 18.7), while the time to treatment start for moderate palsy was 38.76 h (sd ± 14.72) and for mild palsy, 41.47 h (sd ± 17.5).
In group 1, prednisolone showed significant success regarding complete recovery and absence of slinkiness in all cases, this was correlated to the baseline severity where higher results were obtained in mild cases and lower results with severe cases (Table 1) .
In group 2, acyclovir showed significant success regarding complete recovery and absence of slinkiness in all cases, this was also correlated to the baseline severity where higher results were obtained in mild cases and lower results with severe cases (Table 2) .
In group 3, prednisolone and acyclovir showed significant success regarding complete recovery and absence of slinkiness in all cases, this was also correlated to the baseline severity where higher results were obtained in mild cases and lower results with severe cases (Table 3) .
Comparing the results of the three groups, there was a significant difference between group 1 and 2 results (p < .05) reflecting higher results of prednisolone above acyclovir alone regardless of the severity of cases. There was no significant difference between group 1 and 3 results in severe and mild cases while group 3 showed higher results in the moderate group cases (p < .05) as shown in Table 4 .
Time to complete recovery was significantly shorter for groups 1 and 3 for the three severity groups. As expected, mild cases showed significant shorter time for complete recovery than moderate and severe cases. Acyclovir did not add a significant difference to prednisolone regarding this time.
The mean Sunnybrook scores at 12 months were correlated to the severity in all groups where mild cases showed higher scores and severe cases showed lower scores as shown in Table 5 and Fig. 1 .
Synkinesis was present in higher percentage in group 2 (acyclovir group) with no significant difference between groups 1 and 3, as shown in Table 6 .
Discussion
Patients with severe, moderate and mild palsy at presentation, all had significantly higher complete recovery rates if treated with prednisolone compared with acyclovir. Synkinesis at 12 months was also significantly less common in patients when treated with prednisolone as compared with acyclovir in the three severity categories.
In our study, patients with moderate palsy at baseline who were treated with prednisolone plus acyclovir had significantly higher complete recovery rates compared with those treated with prednisolone plus placebo and with acyclovir plus placebo groups.
At the initial visit, the physician cannot predict if the palsy will deteriorate or not. In a study by Linder et al. 13 36% of patients, almost all treated with steroids, deteriorated to total paralysis within 2 weeks. Marsk et al. 20 found that 236/829 (28%) patients with Bell's palsy deteriorated within the first 11-17 days after onset of palsy and that early treatment with prednisolone reduced the number of patients who deteriorated.
Steroid treatment may reduce inflammation and thus prevents further nerve damage. As at present we do not have any diagnostic tool that can, at the initial visit, predict the course and outcome for the individual patient, it seems adequate to treat the patient regardless of severity of palsy. Even Table 1 The effect of prednisolone (plus placebo) on recovery and synkinesis. patients with mild palsies benefit from early treatment with steroids, which is in accordance with other results that treatment with prednisolone within 48 h of onset of palsy gave significantly higher recovery rates and less synkinesis compared with no prednisolone. 21 The addition of acyclovir to prednisolone did not have any significant additional effect regarding complete recovery or presence of synkinesis in the severe and mild groups. This is not in accordance with the findings of Hato et al. 22 Patients in that study were treated with valaciclovir, 1000 mg/day compared with 1200 mg/ day acyclovir in our study, they reported a better outcome with the combination therapy of prednisolone and valaciclovir in cases of complete or severe palsy. In a study by Minnerop et al. 23 the combination of prednisolone with famciclovir was reported to be more effective in cases with severe palsy.
Our findings concerning acyclovir plus placebo are in accordance with those of the Cochrane review 'Antiviral treatment for Bell's palsy' including seven trials with altogether 1987 patients. 6 It was concluded that moderate quality evidence shows that antivirals are significantly less likely to produce complete recovery compared with corticosteroids.
Acyclovir group results were not significantly different from other studies that were performed using placebo alone in the treatment of Bell's palsy. In a study done by Axelsson et al. 24 in patients with severe to mild palsy at baseline, valaciclovir had no effect on complete recovery rates compared with placebo. There was no significant effect of valaciclovir alone on the presence of synkinesis at 12 months in any of the three different severity groups at baseline. 24 In accordance with previous studies, [10] [11] [12] 22 severity at baseline in the present study was correlated to outcome. Consequently, a low Sunnybrook value at baseline was correlated to a less favourable outcome.
Conclusion
Bell's palsy patients given prednisolone had significantly better outcome, regardless of severity of palsy at presentation, compared with patients not treated with prednisolone. Acyclovir had an additional effect to prednisolone in moderate cases of Fig. 1 Comparison between the three groups regarding Sunnybrook score at 12 months. paralysis at presentation. The severity at baseline in the present study was correlated to outcome. We therefore recommend treatment with prednisolone regardless of severity at initial visit in adult patients with Bell's palsy as long as no contraindications for steroid treatment are present. We also recommend the addition of acyclovir to prednisolone in cases categorised as moderate palsy at presentation.
